In conclusion, the multifaceted effects of DPP4i on Aβ and tau pathology, combined with their positive impact on cognitive function, neuroinflammation, oxidative stress, and neuronal survival, present a compelling case for their potential as disease-modifying agents for AD. This evidence concerns the gene MAPT and Alzheimer disease.